Nicolas Escriou

Dr. Nicolas Escriou

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2020 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
LGLudivine Grzelak
Ludivine Grzelak
STSarah Temmam
Sarah Temmam
CPCyril Planchais
Cyril Planchais
CDCaroline Demeret
Caroline Demeret
LTLaura Tondeur
Laura Tondeur
SWSylvie van der Werf
Sylvie van der Werf
Different serological assays measuring anti–SARS-CoV-2 antibodies and their neutralizing activity in samples from individuals with severe and mild COVID-19 are compared.

1 March 2014 in Virology
Verified
Journal Article
Closed access
NENicolas Escriou
Nicolas Escriou
BCBenoît Callendret
Benoît Callendret
VLValérie Lorin
Valérie Lorin
CCChantal Combredet
Chantal Combredet
PMPhilippe Marianneau
Philippe Marianneau
FTFrédéric Tangy
Frédéric Tangy

1 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OLOlivier Leymarie
Olivier Leymarie
GJGrégory Jouvion
Grégory Jouvion
PHPierre-Louis Hervé
Pierre-Louis Hervé
CCChristophe CHEVALIER
Christophe CHEVALIER
VLValérie Lorin
Valérie Lorin
RGRonan Le Goffic
Ronan Le Goffic
The PB1-F2 protein encoded by influenza A viruses can contribute to virulence, a feature that is dependent of its sequence polymorphism. Whereas PB1-F2 from some H1N1 viruses were shown to exacerbate the inflammatory response within the airways, the contribution of PB1-F2 to highly pathogenic avian influenza virus (HPAIV) virulence in mammals remains poorly described. Using a H5N1 HPAIV strain isolated from duck and its PB1-F2 knocked-out mutant, we characterized the dynamics of PB1-F2-associated host response in a murine model of lethal pneumonia. The mean time of death was 10 days for the two viruses, allowing us to perform global transcriptomic analyses and detailed histological investigations of the infected lungs at multiple time points. At day 2 post-infection (pi), while no histopathological lesion was observed, PB1-F2 expression resulted in a significant inhibition of cellular pathways involved in macrophage activation and in a transcriptomic signature suggesting that it promotes damage to the epithelial barrier. At day 4 pi, the gene profile associated with PB1-F2 expression revealed dysfunctions in NK cells activity. At day 8 pi, PB1-F2 expression was strongly associated with increased transcription of genes encoding chemokines and cytokines implicated in the recruitment of granulocytes, as well as expression of a number of genes encoding enzymes expressed by neutrophils. These transcriptomic data were fully supported by the histopathological analysis of the mice lungs which evidenced more severe inflammatory lesions and enhanced recruitment of neutrophils in the context of PB1-F2 expression, and thus provided a functional corroboration to the insight obtained in this work. In summary, our study shows that PB1-F2 of H5N1 HPAIV markedly influences the expression of the host transcriptome in a different way than its H1N1 counterparts: H5N1 PB1-F2 first delays the initial immune response but increases the pulmonary inflammatory response during the late stages of infection.

24 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
LGLudivine Grzelak
Ludivine Grzelak
STSarah Temmam
Sarah Temmam
CPCyril Planchais
Cyril Planchais
CDCaroline Demeret
Caroline Demeret
CHChristèle Huon
Christèle Huon
SWSylvie van der Werf
Sylvie van der Werf
It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their antibody response profile. Here, we performed a pilot study to assess the levels of anti-SARS-CoV-2 antibodies in samples taken from 491 pre-epidemic individuals, 51 patients from Hôpital Bichat (Paris), 209 pauci-symptomatic individuals in the French Oise region and 200 contemporary Oise blood donors. Two in-house ELISA assays, that recognize the full-length nucleoprotein (N) or trimeric Spike (S) ectodomain were implemented. We also developed two novel assays: the S-Flow assay, which is based on the recognition of S at the cell surface by flow-cytometry, and the LIPS assay that recognizes diverse antigens (including S1 or N C-terminal domain) by immunoprecipitation. Overall, the results obtained with the four assays were similar, with differences in sensitivity that can be attributed to the technique and the antigen in use. High antibody titers were associated with neutralisation activity, assessed using infectious SARS-CoV-2 or lentiviral-S pseudotypes. In hospitalized patients, seroconversion and neutralisation occurred on 5-14 days post symptom onset, confirming previous studies. Seropositivity was detected in 29% of pauci-symptomatic individuals within 15 days post-symptoms and 3 % of blood of healthy donors collected in the area of a cluster of COVID cases. Altogether, our assays allow for a broad evaluation of SARS-CoV2 seroprevalence and antibody profiling in different population subsets.

1 December 2015 in Virology
Verified
Journal Article
Closed access
PHPierre-Louis Hervé
Pierre-Louis Hervé
VLValérie Lorin
Valérie Lorin
GJGrégory Jouvion
Grégory Jouvion
BCBruno Da Costa
Bruno Da Costa
NENicolas Escriou
Nicolas Escriou

20 October 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MGMarion Gransagne
Marion Gransagne
GAGabriel Aymé
Gabriel Aymé
SBSébastien Brier
Sébastien Brier
GFGaëlle Chauveau-Le Friec
Gaëlle Chauveau-Le Friec
VMVéronique Meriaux
Véronique Meriaux
PLPierre Lafaye
Pierre Lafaye
The current COVID-19 pandemic illustrates the importance of obtaining reliable methods for the rapid detection of SARS-CoV-2. A highly specific and sensitive diagnostic test able to differentiate the SARS-CoV-2 virus from common human coronaviruses is therefore needed. Coronavirus nucleoprotein (N) localizes to the cytoplasm and the nucleolus and is required for viral RNA synthesis. N is the most abundant coronavirus protein, so it is of utmost importance to develop specific antibodies for its detection. In this study, we developed a sandwich immunoassay to recognize the SARS-CoV-2 N protein. We immunized one alpaca with recombinant SARS-CoV-2 N and constructed a large single variable domain on heavy chain (VHH) antibody library. After phage display selection, seven VHHs recognizing the full N protein were identified by ELISA. These VHHs did not recognize the nucleoproteins of the four common human coronaviruses. Hydrogen Deuterium eXchange–Mass Spectrometry (HDX-MS) analysis also showed that these VHHs mainly targeted conformational epitopes in either the C-terminal or the N-terminal domains. All VHHs were able to recognize SARS-CoV-2 in infected cells or on infected hamster tissues. Moreover, the VHHs could detect the SARS variants B.1.17/alpha, B.1.351/beta, and P1/gamma. We propose that this sandwich immunoassay could be applied to specifically detect the SARS-CoV-2 N in human nasal swabs.